PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Mol Cell Cardiol. Author manuscript; available in PMC 2013 November 1.
Published in final edited form as:
PMCID: PMC3472041
NIHMSID: NIHMS402640

Ca2+ influx through L-type Ca2+ channels and transient receptor potential channels activate pathological hypertrophy signaling

Abstract

Common cardiovascular diseases such as hypertension and myocardial infarction require that myocytes develop greater than normal force to maintain cardiac pump function. This requires increases in [Ca2+]. These diseases induce cardiac hypertrophy and increases in [Ca2+] are known to be an essential proximal signal for activation of hypertrophic genes. However, the source of “hypertrophic” [Ca2+] is not known and is the topic of this study. The role of Ca2+ influx through L-type Ca2+ channels (LTCC), T-type Ca2+ channels (TTCC) and transient receptor potential (TRP) channels on the activation of Calcineurin (Cn) – Nuclear Factor of Activated T cells (NFAT) signaling and myocyte hypertrophy was studied. Neonatal rat (NRVMs) and adult feline (AFVM) ventricular myocytes were infected with an adenovirus containing NFAT-GFP, to determine factors that could induce NFAT nuclear translocation. Four millimolar Ca2+ or pacing induced NFAT nuclear translocation. This effect was blocked by Cn inhibitors. In NRVMs Nifedipine (Nif, LTCC antagonist) blocked high Ca2+-induced NFAT nuclear translocation while SKF-96365 (TRP channel antagonist) and Nickel (Ni, TTCC antagonist) were less effective. The relative potency of these antagonists against Ca2+ induced NFAT nuclear translocation (Nif>SKF-96365>Ni) was similar to their effects on Ca2+ transients and the LTCC current. Infection of NRVM with viruses containing TRP channels also activated NFAT-GFP nuclear translocation and caused myocyte hypertrophy. TRP effects were reduced by SKF-96365, but were more effectively antagonized by Nif. These experiments suggest that Ca2+ influx through LTCCs is the primary source of Ca2+ to activate Cn-NFAT signaling in NRVMs and AFVMs. While TRP channels cause hypertrophy, they appear to do so through a mechanism involving Ca2+ entry via LTCCs.

Keywords: L-type calcium channel, Hypertrophy, Nuclear factor of activated T cells, Ventricular myocyte, Transient receptor potential channel

1. Introduction

Pathological cardiac stress, such as hypertension and myocardial infarction (MI), causes alterations in cardiac myocyte Ca2+ handling[1, 2]. The increase in cytosolic Ca2 activates the calcineurin (Cn)-nuclear factor of activated T cells (NFAT) signaling pathway. Cn-mediated dephosphorylation of NFAT leads to its nuclear translocation where it initiates the expression of genes involved in pathological cardiac hypertrophy. Blocking this pathway has beneficial effects on cardiac structure and function[35]. However, the upstream sources of Ca2+ that initiate pathological hypertrophy through Cn-NFAT signaling are still not clearly established. Recent studies suggest that Cn-NFAT activation may be independent of the global cardiac Ca2+ transient and may take place in signaling microdomains also housing T-type Ca2+ channels[6, 7] or transient receptor potential (TRP) channels[811]. Other studies have suggested that Cn-NFAT signaling is sensitive to changes in the rate and amplitude of the systolic Ca2+ transient[12, 13]. A recent study from our group suggests that L-type Ca2+ channels housed in caveolae, away from excitation-contraction coupling proteins are a local microdomain for Ca2+-activation of Cn-NFAT signaling[14].

The role of Cn-NFAT signaling in the induction of pathological hypertrophy was first proposed by Molkentin et al.[15]. This study showed that when a constitutively activated Cn was expressed in cardiac myocytes of transgenic mice, pathological cardiac hypertrophy developed and resulted in heart failure. Many studies have since shown that this pathological Cn-NFAT signaling pathway is activated by increases in Ca2+. When the intracellular Ca2+ concentration is elevated, Ca2+ ions bind to calmodulin (CaM) and the Ca2+/CaM complex activates the protein phosphatase Cn. Activated Cn subsequently dephosphorylates its downstream substrate, NFAT. Dephosphorylated NFAT translocates from the cytosol into the nucleus and activates transcription factors (e.g. GATA4), which initiate hypertrophic gene expression[16]. The source of the Ca2+ that activates pathological Cn-NFAT signaling is still not well known and is the topic of this study.

One possible source of Ca2+ that activates the Ca2+/CaM-Cn-NFAT pathway in the heart is the high-conductance, voltage-regulated L-type Ca2+ channels (LTCC). These channels provide the Ca2+ influx that is essential for inducing and regulating myocyte contraction. This Ca2+ influx is essential for triggering sarcoplasmic reticulum (SR) Ca2+ release (CICR)[17]. There is some evidence that Ca2+ entry through the LTCC can induce pathological hypertrophy[18, 19]. In myocytes isolated from animal models of hypertrophy[2024] or from failing human hearts[25], the L-type Ca2+ current density is unchanged or slightly elevated[26]. However, these measurements are made in the absence of the sympathetic agonists that increase Ca2+ current and are increased in cardiovascular diseases[2729]. Therefore, in-vivo, LTCC current is increased in disease and is a possible source of Ca2+ to activate pathological signaling[3034]. Further support for a role for LTCCs comes from studies that have shown beneficial effects of LTCC antagonists on cardiac remodeling in distinct hypertrophy and heart failure models[5]. However there are numerous studies suggesting that other Ca2+ influx pathways are the primary source of “hypertrophic” Ca2+. Experiments in the present study support the idea that LTCCs are the primary source of Ca2+ to activate Cn-NFAT signaling in NRVMs and AFVMs.

Ca2+ can also enter cardiac myocytes through T-type Ca2+ channels (TTCC), which are normally expressed throughout cardiac development until the end of the neonatal period[3537]. TTCC expression decreases after birth with little expression in normal adult ventricular myocytes. However, TTCCs are re-expressed when the heart is subjected to pathological stresses, suggesting a role in cardiac hypertrophy and failure[3842]. Ca2+ influx through TTCC has almost no effect on EC coupling[43]. Cav3.1 (α1G) and Cav3.2 (α1H) are the major TTCC isoforms in the heart[44]. A few studies support the idea that Ca2+ influx through TTCCs can activate Cn-NFAT signaling and cause hypertrophy in neonatal cardiac myocytes, when TTCC expression is robust[7]. There are also studies supporting the idea that Ca2+ influx through TTCC causes pathological hypertrophy in the adult heart. One study[45] in a mouse model of dilated cardiomyopathy, reported that the R(−)-isoform of efonidipine, a highly selective TTCC antagonist improved survival. Another study[6] showed that pressure overload-induced hypertrophy was suppressed in Cav3.2 knockout (Cav3.2−/ −) mice. Angiotensin II-induced cardiac hypertrophy was also reduced in these mice and the activation of NFAT was blunted following pressure overload. However, there are other studies that do not support a roll of TTCC as a source of Ca2+ for cardiac hypertrophy[43, 46]. Mice overexpressing Cav3.1 and with large TTCC currents did not have cardiac hypertrophy[43]. In fact, when these animals were subjected to pathological stress their hypertrophy was smaller than in wild type animals, suggesting that Ca2+ influx through TTCCs is antihypertrophic[46]. The role of Ca2+ influx through TTCCs in pathological hypertrophy remains unresolved.

Ca2+ can also enter cardiac myocytes through Transient Receptor Potential (TRP) channels. TRP channels are nonselective cation channel subunits responsible for receptor activated Ca2+ entry and possibly having a role in store operated Ca2+ entry (SOCE)[47]. TRP channels have been grouped into 7 subfamilies[48, 49]. Several studies have reported that the canonical TRP channels (TRPC) are involved in cardiac hypertrophy and heart failure[49]. TRPC have 7 family members and are divided into 2 subgroups based on their primary amino acid sequences and functions. TRPC1, C3–7 are expressed in the heart[50, 51] and TRPC3 expression is up-regulated in multiple rodent models of pathological cardiac hypertrophy[52]. There is some evidence that TRPC promotes cardiomyocyte hypertrophy through activation of Cn-NFAT signaling[9] This effect was blocked by the store operated Ca2+ entry (SOCE) antagonist SKF-96365. Small interference RNA-mediated knockdown of TRPC3 and TRPC6 has also been shown to attenuate Ang II-induced NFAT activation and myocyte hypertrophy[10]. Cardiac-specific overexpression of TRPC6 in transgenic mice sensitizes the heart to pathologic hypertrophic signaling, leading to cardiac dysfunction, hypertrophy and increased β-myosin heavy chain expression, which is regulated by Cn-NFAT signaling[11]. Collectively these studies suggest that Ca2+ influx through TRP channels can activate pathological hypertrophy signaling.

In the present experiments we tested the respective ability of Ca2+ influx through the LTCCs, TTCCs and TRPC channels to activate Cn-NFAT signaling and cause myocyte hypertrophy. NVRMs or AFVMs infected with NFATc3-GFP were used to examine the source of Ca2+ to promote NFAT nuclear translocation. Our results suggest that LTCCs and TRPs can supply Ca2+ to activate pathological hypertrophy, at least under the conditions of our experiments.

2. Materials and methods

2.1. Cell isolation and culture

Neonatal rat ventricular myocytes (NRVMs) were isolated from 1- to 3-day-old Sprague Dawley rats as described previously[53, 54]. NRVMs were cultured in DMEM with 5% fetal bovine serum for 24 hr. Then the cells were cultured in non-serum media and infected with an adenovirus encoding NFATc3-GFP to monitor NFAT localization. Addition of 4 mM extracellular Ca2+ was used to stimulate Ca2+ influx. The L-type Ca2+ channel blocker Nifedipine (Nif), T-type Ca2+ channel blocker Ni2+ and TRP channel blocker (SKF-96365) were used just before addition of Ca2+. AFVMs were isolated and cultured using approaches described in detail previously[14].

2.2. Immunocytochemistry and confocal imaging

Myocytes were cultured on coverslips coated with fibronectin (BD Sciences). After treatment with increased Ca2+ for 4 hours, cells were fixed in 4% paraformaldehyde at room temperature for 10 minutes and permeabilized with 0.5% Triton X-100 immediately before labeling with antibodies directed against α-actinin. Staining of α-actinin and DAPI was performed to detect myocytes and location of nuclei. Fixed cells on coverslips were mounted onto slides and observed with a confocal microscope (Nikon). Images were analyzed with EZ-C1 FreeViewer (Nikon) and ImageJ (NIH) software. NFAT localization was quantified as the normalized nucleus/cytoplasm ratio of GFP fluorescence intensity (NFATn/c).

2.3. Cell surface area measurement

To evaluate ventricular myocyte hypertrophy, cell surface area was measured in NRVMs as described in detail previously[5557].

2.4. Ca2+ current measurement

Measurement of L-type Ca2+ current (ICa-L) was measured as described previously[54]. Briefly, ICa-L was measured with whole-cell voltage clamp techniques with pipettes (2–4 MΩ) containing (mM): 130 CsOH, 130 aspartic acid, 10 EGTA, 1 MgCl2, 10 NMDG, 10 HEPES, 20 TEA-Cl, 5 Tris-ATP, pH 7.2. After 30 seconds of dialysis, cells were perfused with a Na-free, K-free solution containing (mM): 2 CaCl2, 2 4-AP, 5.4 CsCl, 10 Glucose, 5 HEPES, 1.2 MgCl2, 150 NMDG, pH 7.4. ICa-L was measured from a -50 mV holding potential (TTCC are inactivated). All experiments were performed using the Axopatch 2 voltage-clamp amplifier and Clampex10 software (Molecular Devices).

2.5. Ca2+ transient measurements

Ca2+ transients were measured as previously described[58]. Cultured NRVMs were loaded with fluo 4-AM were perfused with normal Tyrode s solution containing 1mM Ca2+. Cells were paced at 0.5Hz and Ca2+ transients were recorded using Clampex 10 software.

2.6. Statistics

Data are presented as mean ± SEM. Unpaired t-test, paired t-test, and one-way ANOVA were performed to detect significance using GraphPad Prism 5.0 (GraphPad Software). P≤0.05 was considered significant. “n” is the number of cells examined.

3. Results

3.1. Effects of Ca2+ channel antagonists on Ca2+ transients

The first series of experiments determined the effects of Nifedipine (a dihydropyridine LTCC antagonist, 10μM), Ni2+ (TTCC antagonist, 50μM) and SKF-96365 (TRPC blocker, 5μM) on Ca2+ transients of cultured NRVMs (Figure 1). These Ca2+ channel antagonists reduced the amplitude of the Ca2+ transients by 79%, 33%, and 20%, respectively. These results suggest that all three channel types are present in NRVMs and that LTCCs are the major source of Ca2+ to produce the Ca2+ transient.

Figure 1
Nifedipine, SKF-96365, and Ni2+ have distinct effect on Ca2+ transients. Ca2+ transients were measured in NRVMs perfused with normal Tyrode s solution (Ctrl) before and after exposure to solutions containing either 10μM Nifedipine (Nif, A), 5μM ...

3.2. Effects of Ca2+ channel antagonists on Ca2+ transients on the L-type Ca2+ current

The effects of these three channel blockers on L-type Ca2+ current were examined, to ensure that putative TTCC and TRPC channel antagonists did not block the LTCC. Nifedipine blocked the majority of ICa-L in cultured NRVMs (Figure 2). Peak ICa-L decreased to a low level within 2 min after perfusion with 10 μM Nifedipine. Neither SKF-96365 nor Ni2+ had a significant effect on ICa-L under our experiment conditions.

Figure 2
Nifedipine blocked L-type Ca2+ current. Ten micromolar Nif reduced L-type Ca2+ current by 64.03% (A, B). SKF-96365 (5μM) and Ni2+ (50μM) had no significant effect on peak L-type Ca2+ current. Nif significantly inhibited peak ICa-L currents ...

3.3. Ca2+ induced NFAT nuclear translocation

NFAT translocation from the cytoplasm to the nucleus can be reliably induced by elevation of the extracellular Ca2+ concentration in NRVM and AFVMs[59]. We tested the effect of 10μM Nifedipine, 5μM SKF-96365, and 50μM Ni2+on Ca2+ induced NFATc3 translocation (Figure 3). Exposure to 4 mM Ca2+ for 4 hours significantly increased the ratio of nuclear GFP fluorescence intensity to cytoplasmic GFP fluorescence intensity (NFATn/c was 9.37 ± 0.55, n=240, in 4 mM Ca2+-treated cells vs. 1.00 ± 0.09, n=227, in control, P<0.05). Ca2+ induced nuclear NFAT translocation was almost abolished by Nifedipine (NFATn/c was 1.10 ± 0.12, n=19) and was reduced by SKF-96365 (NFATn/c was 3.52 ± 0.82, n=27), and Ni2+ (NFATn/c was 5.70 ± 0.69, n=26). Ni2+ was the least effective treatment we tested. The relative potency of 10μM Nifedipine, 5μM SKF-96365, and 50μM Ni2+ on Ca2+ induced NFAT nuclear translocation mirrored the effects of these agents on the Ca2+ transient (Figure 1). NFAT nuclear translocation was induced in AFVMs by pacing for 80 min (Supplementary Figure 1). Nifedipine abolished pacing induced NFAT nuclear translocation. Ni2+ and SKF-96365 had no effect on pacing induced NFAT nuclear translocation in AFVMs (not shown). TRP channels often require activation through G-protein coupled receptors that lead to diacyglycerol (DAG) production. NFAT was translocated to the nucleus in AFVMs exposed to OAG. This effect was abolished when myocytes were infected with a dominant negative (dn)-TRPC6 adenovirus. Nif also abolished the OAG effect (Supplementary Figure 2). These results suggest that activation of TRPC channels in AFVMs can promote hypertrophic signaling and as in NRVMs there is an obligatory role of Ca2+ influx through LTCCs.

Figure 3
Ca2+ channel inhibitors blocked Ca2+ influx induced NFATc3 nuclear translocation. NRVMs were infected with Ad-NFATc3-GFP and exposed to vehicle (Ctrl, A), 4mM Ca2+ (B), 4mM Ca2+ with 10μM Nifedipine (C), 4mM Ca2+ with 5μM SKF-96365 (D), ...

3.4. CsA and FK506 inhibited Ca2+-induced NFAT translocation (Figure 4)

Our hypothesis is that Ca2+-induced NFAT nuclear translocation in our preparations results from Ca2+ mediated activation of Cn. To verify the role of Cn in this process NRVMs were pretreated with either cyclosporine A (CsA) or FK506 (known Cn inhibitors) before increasing bath [Ca2+]. Both CsA and FK506 completely inhibited (and actually reduced) NFAT nuclear translocation induced by elevated Ca2+ concentration (NFATn/c was 0.41 ± 0.02, n=55, in CsA treated cells and 0.48 ± 0.01, n=98, in FK506 treated cells vs. 8.07 ± 0.79, n=115, in NRVMs with Ca2+ treatment, P<0.05). These observations support the hypothesis that in this system elevation of bath [Ca2+] activates Cn to induce translocation of NFAT from the cytoplasm to the nucleus.

Figure 4
Calcineurin inhibitors blocked Ca2+-induced NFAT translocation. CsA (2μM) and FK506 (2μM) both abolished Ca2+-induced NFAT nuclear translocation. * indicates a significant difference versus control. # indicates a significant difference ...

3.5 TRPC overexpression increases cell surface area

The experiments with the TRP antagonist SKF-96365 suggest that Ca2+ influx through TRP channels can activate Cn-NFAT signaling. To further explore this idea NRVM were infected with Ad-TRPC3 (Figure 5). TRPC3 increased cell surface area (1.86 ± 0.06, n=57, in Ad-TRPC3 infected cells vs. 1.00 ± 0.04, n=57, in control, P<0.05). SKF-96365 (1.30 ± 0.05, n=57), and FK506 (1.10 ± 0.04, n=50), blocked the TRPC3 induced myocyte hypertrophy. Interestingly, Nif also blocked NRVM hypertrophy induced by TRPC3 (1.17 ± 0.05, n=74, in Nif treated cells vs. 1.86 ± 0.06, n=57, in Ad-TRPC3 infected cells, P<0.05). Ni2+ (1.74 ± 0.08, n=44) had no significant effect on TRPC3 induced myocyte hypertrophy. Elevation of bath [Ca2+] and Ad-TRPC3 also increased ANP abundance, consistent with the activation of hypertrophic gene expression (Supplementary Figure 3).

Figure 5
TRPC3 induced NRVM hypertrophy (A, B, G). Nifedipine (10μM, C, G) and SKF-96365 (5μM, D, H) caused a significant reduction in TRPC3 induced hypertrophy while Ni2+ (50μM, E, G) had no effect. FK506 (2μM, F, G) inhibited ...

3.6. Ca2+ influx through TRPC3 induces NFAT translocation (Figure 6)

Infection of NRVMs with ad-TRPC3 induced NFAT nuclear translocation without elevation of extracellular Ca2+ (NFATn/c was 5.51 ± 0.48, n=153, in Ad-TRPC3 infected cells vs. 1.00 ± 0.09, n=149, in control, P<0.05). Elevating bath [Ca2+] induced further NFAT translocation in TRPC3 infected NRVMs (NFATn/c was 9.23 ± 1.03, n=59). Infection of NRVMs with Ad-dnTRPC6 inhibited most of the NFAT nuclear translocation induced by elevated bath [Ca2+] (NFATn/c was 2.60 ± 0.45, n=127, in Ad-dnTRPC6 infected-cells with Ca2+ treatment vs. 8.66 ± 0.98, n=80, in Ca2+ treated cells, P<0.05).

Figure 6
TRPC3 induced NFAT-GFP nuclear translocation (A, B, G). NRVMs were infected with Ad-NFATc3-GFP alone, Ad-NFATc3-GFP and Ad-TRPC3, and Ad-NFATc3-GFP and Ad-dnTRPC6 (A–G), respectively. Elevated extracellular Ca2+ induced NFAT translocation in control ...

3.7 Nifedipine blocks NFAT translocation induced by TRPC3 overexpression

As shown above, Nifedipine inhibited the hypertrophy induced by expression of TRPC3 in NRVMS. The next experiments defined the effects of 10μM Nifedipine, 5μM SKF-96365, and 50μM Ni2+ on TRPC3 induced NFAT nuclear translocation (Figure 7). FK506 completely blocked NFATc3 translocation induced by TRPC3, documenting the essential role of Cn in this process. SKF-96365 blocked some but not all of the NFATc3 translocation in TRPC3 infected myocytes. Ni2+ had no affect on TRPC3 overexpression-induced NFATc3 translocation. Nif completed blocked TRPC3 induced nuclear NFAT translocation. These finding support a scenario in which TRP channels influence LTCCs to activate Cn-NFAT signaling. The nature of this effect remains to be defined. We did find that TRPC3 infected cells had increased LTCC protein abundance (Supplementary Figure 3) and amplitude of the LTCC current (Supplementary Figure 4).

Figure 7
Nifedipine blocked NFAT translocation induced by TRPC3 overexpression (A, B, C, G). SKF-96365 (5μM, D) reduced TRPC3-induced NFAT nuclear translocation but was less effective than Nif. Ni2+ (50μM, E) had no significant effect on TRPC3 ...

3.8 TRPC3 expression alters the Ca2+ transient

The results above suggest that TRP channels might influence the number and/or behavior of LTCCs to provide the Ca2+ that induces cardiac myocyte hypertrophy. If so, there might also be an effect on the global [Ca2+] transient that initiates contraction. To explore this idea Ca2+ transients were measured in NRVMs infected with Ad-TRPC3 (Figure 8) The peak of the Ca2+ transient was not significantly different between control and Ad-TRPC3-infected cells (B). However, Time to half decay was significantly prolonged in NRVMs infected with Ad-TRPC3 as compared with control (C). These results are consistent with an interaction of TRPC3 and LTCCs that leads to activation of Cn-NFAT signaling.

Figure 8
TRPC3 prolonged the Ca2+ transient (A). The peak of Ca2+ transient was not significantly altered in TRPC3-infected cells (B). The time to half decay was significantly prolonged in NRVMs infected with Ad-TRPC3 versus controls (C).

4. Discussion

The present study explored the respective roles of Ca2+ influx through L- and T-type Ca2+ channels and TRP channels in the activation of the Cn-NFAT signaling. Activation of this signaling pathway is involved in the induction of pathological cardiac hypertrophy[60]. The major findings of this study are that Ca2+ influx through the LTCC is the major source of Ca2+ to activate Cn-NFAT signaling, at least in the preparations used in the current experiments. Ca2+ influx through TRP channels also appeared to be able to activate this signaling cascade, while Ca2+ influx through TTCC was least able to induce myocyte hypertrophy. The most novel aspect of the study is those findings that suggest an interaction between TRP and LTCC channels to activate Cn-NFAT signaling and induce myocyte hypertrophy. The nature of this interaction deserves additional study.

Cytoplasmic [Ca2+] during diastole falls to about 150nM (when the cells are relaxed and the heart is filling with blood) and is rapidly increased during each heartbeat to induce contraction. Changes in the amplitude and duration of the Ca2+ transient largely determine the strength (contractility) of the heartbeat[2]. In cardiac diseases such as hypertension and after myocardial infarction, the myocytes must beat more forcefully to maintain cardiac output against a pathologically elevated afterload. This requires an increase in cytosolic Ca2+. In these diseases, cardiac myocytes undergo “pathological” hypertrophy and this is associated with cardiac dysfunction, arrhythmias and sudden arrhythmogenic death[61]. It is known that the persistent increase in myocyte Ca2+ in the diseased heart is linked to pathological hypertrophy, but the actual source of Ca2+ is not clearly defined[1]. Most recent studies suggest that the global Ca2+ transient that initiates contraction is not the source of Ca2+ to activate Cn-NFAT signaling and cardiac hypertrophy. Maybe the two best examples of this are the phospholamban knock out mouse[62] and the TTCC, α1g, overexpression mouse[43]. Both of these mice have hypercontractile hearts with a persistent increase in the amplitude of the systolic Ca2+ transient. However, there is no pathological hypertrophy in these mice. In fact, the α1g mouse appears to be protected from hypertrophy. These studies suggest that the amplitude of the global Ca2+ transient is not the activator of Cn-NFAT signaling and suggest that a local source of Ca2+ might be responsible for activation of this signaling cascade. Our study explored three potential Ca2+ influx pathways as the source of “hypertrophic Ca2+”.

L-type Ca2+ channels are the major pathway for Ca2+ entry in the heart. These channels activate with the depolarization during each action potential and the resultant Ca2+ entry elevates submembrane [Ca2+] within an EC coupling microdomain (the couplon ) where it induces opening of the SR Ca2+ release channel (RyR) to initiate SR Ca2+ release[63]. The role of Ca2+ influx through these channels in the activation of pathological hypertrophy is not clear. As an example, Ca2+ influx through LTCCs increases with exercise or pregnancy, but this does not initiate pathological hypertrophy[60]. However, there are many studies that show that pharmacological reduction of Ca2+ entry through LTCCs in animals or cells reduces pathological hypertrophy[3, 5]. Recently we have shown that a subpopulation of LTCCs in caveolae signaling microdomains can activate Cn-NFAT signaling[14]. In the present studies we show that LTCCs are a major source of Ca2+ to activate Cn-NFAT signaling. Interestingly, TRP channels appear to activate Cn-NFAT signaling by a mechanism that involves the LTCCs (see below). Our studies cannot determine if the LTCCs that provide the Ca2+ to activate Cn-NFAT signaling are independent of those that initiate contraction. This topic deserves additional study. We did find that the relative potency of LTCC, TTCC and TRP channel antagonists on contraction was similar to their ability to block Cn-NFAT signaling. However, this does not mean that the same channels that are involved in EC coupling activate Cn-NFAT signaling.

T-type Ca2+ channels were the least effective activators of Cn-NFAT signaling in the present studies. These results support findings we have made in mice that overexpress these channels, in which Ca2+ influx through these channels appears to be antihypertrophic and cardioprotective[43]. Why others[6, 7] have found an important role for these channels in the induction of pathological hypertrophy is unclear.

TRP channel expression is increased in hearts with pathological stress and their presence has been linked to the induction and maintenance of pathological hypertrophy[8, 64]. The mechanism by which these channels induce pathological hypertrophy is unclear, at least to us, but is thought to involve Ca2+ influx through the TRP channels[810]. Our studies show that these TRP channels can induce activation of Cn-NFAT signaling. Two independent observations in our studies support an interaction between TRP and LTCC channels to activate Cn-NFAT signaling. First, TRPC3-induced Cn-NFAT activation (Figure 7) and myocyte hypertrophy (Figure 6) were bothentirely blocked by selective LTCC blockers. Secondly, infecting myocytes with dnTRPC6 significantly reduced Ca2+-induced activation of Cn-NFAT (Figure 6) that was shown to be the result of Ca2+ entry through LTCCs (Figure 3). Collectively our results suggest that TRP channels modulate the activity/abundance of the LTCCs, and it is the Ca2+ influx through TRP-modified LTCCs that activates Cn-NFAT signaling. This idea will require substantial additional testing.

5. Conclusions

In summary, our results suggest that Ca2+ influx through the LTCC is the major source of Ca2+ to activate the signaling cascade that is known to cause pathological hypertrophy in NRVM and AFVMs. TTCCs were not a major source of hypertrophic Ca2+. The most surprising aspect of this study is the finding that gain and loss of function experiments with TRP channels induce/block hypertrophic signaling through an LTCC dependent mechanism.

Highlights

  • Elevated Ca2+ and pacing induced NFAT nuclear translocation.
  • Nifedipine inhibited Ca2+ transient, LTCC current, and NFAT translocation.
  • Nifedipine blocked TRPc3 induced NFAT translocation and hypertrophy.
  • Ca2+ influx through LTCC is primary source of Ca2+ to activate Cn-NFAT signaling
  • Hypertrophy resulting from TRP channel is involved in Ca2+ entry via LTCC.

Supplementary Material

01

Footnotes

Disclosures

None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Houser SR, Molkentin JD. Does Contractile Ca2+ Control Calcineurin-NFAT Signaling and Pathological Hypertrophy in Cardiac Myocytes? Sci Signal. 2008;1:pe31. [PMC free article] [PubMed]
2. Bers DM, Guo T. Calcium Signaling in Cardiac Ventricular Myocytes. Annals of the New York Academy of Sciences. 2005;1047:86–98. [PubMed]
3. Chen X, Nakayama H, Zhang X, Ai X, Harris DM, Tang M, et al. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. Journal of Molecular and Cellular Cardiology. 2011;50:460–70. [PMC free article] [PubMed]
4. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. The Journal of Clinical Investigation. 2002;109:1013–20. [PMC free article] [PubMed]
5. Ago T, Yang Y, Zhai P, Sadoshima J. Nifedipine Inhibits Cardiac Hypertrophy and Left Ventricular Dysfunction in Response to Pressure Overload. Journal of Cardiovascular Translational Research. 2010;3:304–13. [PMC free article] [PubMed]
6. Chiang C-S, Huang C-H, Chieng H, Chang Y-T, Chang D, Chen J-J, et al. The CaV3.2 T-Type Ca2+ Channel Is Required for Pressure Overload-Induced Cardiac Hypertrophy in Mice. Circ Res. 2009;104:522–30. [PubMed]
7. Horiba M, Muto T, Ueda N, Opthof T, Miwa K, Hojo M, et al. T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers. Life Sciences. 2008;82:554–60. [PubMed]
8. Wu X, Eder P, Chang B, Molkentin JD. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proceedings of the National Academy of Sciences. 2010;107:7000–5. [PubMed]
9. Nakayama H, Wilkin BJ, Bodi I, Molkentin JD. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J. 2006;20:1660–70. [PMC free article] [PubMed]
10. Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 2006;25:5305–16. [PubMed]
11. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. The Journal of Clinical Investigation. 2006;116:3114–26. [PMC free article] [PubMed]
12. Tavi P, Pikkarainen S, Ronkainen J, Niemelä P, Ilves M, Weckström M, et al. Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression. The Journal of Physiology. 2004;554:309–20. [PubMed]
13. Xia Y, McMillin JB, Lewis A, Moore M, Zhu WG, Williams RS, et al. Electrical Stimulation of Neonatal Cardiac Myocytes Activates the NFAT3 and GATA4 Pathways and Up-regulates the Adenylosuccinate Synthetase 1 Gene. Journal of Biological Chemistry. 2000;275:1855–63. [PubMed]
14. Makarewich CA, Correll RN, Gao H, Zhang H, Yang B, Berretta RM, et al. A Caveolae-Targeted L-Type Ca2+ Channel Antagonist Inhibits Hypertrophic Signaling Without Reducing Cardiac Contractility / Novelty and Significance. Circulation Research. 2012;110:669–74. [PMC free article] [PubMed]
15. Molkentin JD, Lu J-R, Antos CL, Markham B, Richardson J, Robbins J, et al. A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy. Cell. 1998;93:215–28. [PubMed]
16. Wilkins BJ, Molkentin JD. Calcium–calcineurin signaling in the regulation of cardiac hypertrophy. Biochemical and Biophysical Research Communications. 2004;322:1178–91. [PubMed]
17. Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A. The L-type calcium channel in the heart: the beat goes on. The Journal of Clinical Investigation. 2005;115:3306–17. [PMC free article] [PubMed]
18. Viola HM, Macdonald WA, Tang H, Hool LC. The L-type Ca(2+) channel as a therapeutic target in heart disease. Curr Med Chem. 2009;16:3341–58. [PubMed]
19. Richard S, Perrier E, Fauconnier J, Perrier R, Pereira L, Gomez AM, et al. ‘Ca(2+)-induced Ca(2+) entry’ or how the L-type Ca(2+) channel remodels its own signalling pathway in cardiac cells. Prog Biophys Mol Biol. 2006;90:118–35. [PubMed]
20. Kleiman RB, Houser SR. Calcium currents in normal and hypertrophied isolated feline ventricular myocytes. Am J Physiol. 1988;255:H1434–42. [PubMed]
21. Rannou F, Sainte-Beuve C, Oliviero P, Do E, Trouvé P, Charlemagne D. The effects of compensated cardiac hypertrophy on dihydropyridine and ryanodine receptors in rat, ferret and guinea-pig hearts. Journal of Molecular and Cellular Cardiology. 1995;27:1225–34. [PubMed]
22. Meszaros J, Coutinho J, Bryant S, Ryder K, Hart G. L-type calcium current in catecholamine-induced cardiac hypertrophy in the rat. Experimental Physiology. 1997;82:71–83. [PubMed]
23. Momtaz A, Coulombe A, Richer P, Mercadier J-J, Coraboeuf E. Action Potential and Plateau Ionic Currents in Moderately and Severely DOCA-salt Hypertrophied Rat Hearts. Journal of Molecular and Cellular Cardiology. 1996;28:2511–22. [PubMed]
24. Gómez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, et al. Defective Excitation-Contraction Coupling in Experimental Cardiac Hypertrophy and Heart Failure. Science. 1997;276:800–6. [PubMed]
25. Chen X, Piacentino V, III, Furukawa S, Goldman B, Margulies KB, Houser SR. L-Type Ca2+ Channel Density and Regulation Are Altered in Failing Human Ventricular Myocytes and Recover After Support With Mechanical Assist Devices. Circ Res. 2002;91:517–24. [PubMed]
26. Mukherjee R, Spinale FG. L-type Calcium Channel Abundance and Function with Cardiac Hypertrophy and Failure: A Review. Journal of Molecular and Cellular Cardiology. 1998;30:1899–916. [PubMed]
27. Strand AH, Gudmundsdottir H, Os I, Smith G, Westheim AS, Bjørnerheim R, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. Journal of Hypertension. 2006;24:905–13. [PubMed]
28. Schlaich MP, Kaye DM, Lambert E, Hastings J, Campbell DJ, Lambert G, et al. Angiotensin II and norepinephrine release: interaction and effects on the heart. Journal of Hypertension. 2005;23:1077–82. [PubMed]
29. Kelm M, Schäfer S, Mingers S, Heydthausen M, Vogt M, Motz W, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. Journal of Hypertension. 1996;14:1357–64. [PubMed]
30. Shimada T, Yoshiyama M, Takeuchi K, Omura T, Takemoto Y, Kim S, et al. Long acting calcium antagonist amlodipine prevents left ventricular remodeling after myocardial infarction in rats. Cardiovasc Res. 1998;37:618–26. [PubMed]
31. Massart P-E, Donckier J, Kyselovic J, Godfraind T, Heyndrickx GR, Wibo M. Carvedilol and Lacidipine Prevent Cardiac Hypertrophy and Endothelin-1 Gene Overexpression After Aortic Banding. Hypertension. 1999;34:1197–201. [PubMed]
32. Schwitter J, DeMarco T, Globits S, Sakuma H, Klinski C, Chatterjee K, et al. Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: Possible interaction with cyclosporine medication. The Journal of Heart and Lung Transplantation. 1999;18:1003–13. [PubMed]
33. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IGP, Schoen FJ, et al. An abnormal Ca2+ response in mutant sarcomere protein–mediated familial hypertrophic cardiomyopathy. The Journal of Clinical Investigation. 2000;106:1351–9. [PMC free article] [PubMed]
34. Gao F, Gong B, Christopher TA, Lopez BL, Karasawa A, Ma XL. Anti-apoptotic effect of benidipine, a long-lasting vasodilating calcium antagonist, in ischaemic/reperfused myocardial cells. British Journal of Pharmacology. 2001;132:869–78. [PMC free article] [PubMed]
35. Nuss HB, Houser SR. Effect of duration of depolarisation on contraction of normal and hypertrophied feline ventricular myocytes. Cardiovasc Res. 1994;28:1482–9. [PubMed]
36. Cribbs LL, Martin BL, Schroder EA, Keller BB, Delisle BP, Satin J. Identification of the t-type calcium channel (Ca(v)3.1d) in developing mouse heart. Circ Res. 2001;88:403–7. [PubMed]
37. Qu Y, Boutjdir M. Gene Expression of SERCA2a and L- and T-type Ca Channels during Human Heart Development. Pediatric Research November. 2001;50:569–74. [PubMed]
38. Nuss HB, Houser SR. T-type Ca2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777–82. [PubMed]
39. Martínez ML, Heredia MP, Delgado C. Expression of T-type Ca2+Channels in Ventricular Cells from Hypertrophied Rat Hearts. Journal of Molecular and Cellular Cardiology. 1999;31:1617–25. [PubMed]
40. Huang B, Qin D, Deng L, Boutjdir M, El-Sherif N. Reexpression of T-type Ca2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res. 2000;46:442–9. [PubMed]
41. Ferron L, Capuano V, Ruchon Y, Deroubaix E, Coulombe A, Renaud J-F. Angiotensin II Signaling Pathways Mediate Expression of Cardiac T-Type Calcium Channels. Circ Res. 2003;93:1241–8. [PubMed]
42. Izumi T, Kihara Y, Sarai N, Yoneda T, Iwanaga Y, Inagaki K, et al. Reinduction of T-Type Calcium Channels by Endothelin-1 in Failing Hearts In Vivo and in Adult Rat Ventricular Myocytes In Vitro. Circulation. 2003;108:2530–5. [PubMed]
43. Jaleel N, Nakayama H, Chen X, Kubo H, MacDonnell S, Zhang H, et al. Ca2+ Influx Through T- and L-Type Ca2+ Channels Have Different Effects on Myocyte Contractility and Induce Unique Cardiac Phenotypes. Circ Res. 2008;103:1109–19. [PMC free article] [PubMed]
44. Vassort G, Talavera K, Alvarez JL. Role of T-type Ca2+ channels in the heart. Cell Calcium. 2006;40:205–20. [PubMed]
45. Kinoshita H, Kuwahara K, Takano M, Arai Y, Kuwabara Y, Yasuno S, et al. T-Type Ca2+ Channel Blockade Prevents Sudden Death in Mice With Heart Failure. Circulation. 2009;120:743–52. [PubMed]
46. Nakayama H, Bodi I, Correll RN, Chen X, Lorenz J, Houser SR, et al. α1G-dependent T-type Ca2+ current antagonizes cardiac hypertrophy through a NOS3-dependent mechanism in mice. The Journal of Clinical Investigation. 2009;119:3787–96. [PMC free article] [PubMed]
47. Hofmann T, Schaefer M, Schultz G, Gudermann T. Transient receptor potential channels as molecular substrates of receptor-mediated cation entry. Journal of Molecular Medicine. 2000;78:14–25. [PubMed]
48. Nelson PL, Beck A, Cheng H. Transient receptor proteins illuminated: Current views on TRPs and disease. The Veterinary Journal. 2011;187:153–64. [PubMed]
49. Eder P, Molkentin JD. TRPC Channels As Effectors of Cardiac Hypertrophy. Circ Res. 2011;108:265–72. [PubMed]
50. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, et al. Transient Receptor Potential Channels in Cardiovascular Function and Disease. Circ Res. 2006;99:119–31. [PubMed]
51. Guinamard R, Bois P. Involvement of transient receptor potential proteins in cardiac hypertrophy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2007;1772:885–94. [PubMed]
52. Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, Bristow MR, et al. Canonical Transient Receptor Potential Channels Promote Cardiomyocyte Hypertrophy through Activation of Calcineurin Signaling. Journal of Biological Chemistry. 2006;281:33487–96. [PubMed]
53. Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res. 1982;50:101–16. [PubMed]
54. Gaughan JP, Hefner CA, Houser SR. Electrophysiological properties of neonatal rat ventricular myocytes with alpha 1-adrenergic-induced hypertrophy. Am J Physiol Heart Circ Physiol. 1998;275:H577–90. [PubMed]
55. Silver LH, Hemwall EL, Marino TA, Houser SR. Isolation and morphology of calcium-tolerant feline ventricular myocytes. Am J Physiol. 1983;245:H891–6. [PubMed]
56. Alibin CP, Kopilas MA, Anderson HDI. Suppression of Cardiac Myocyte Hypertrophy by Conjugated Linoleic Acid. Journal of Biological Chemistry. 2008;283:10707–15. [PubMed]
57. Anderson HDI, Wang F, Gardner DG. Role of the Epidermal Growth Factor Receptor in Signaling Strain-dependent Activation of the Brain Natriuretic Peptide Gene. Journal of Biological Chemistry. 2004;279:9287–97. [PubMed]
58. Wang W, Zhang H, Gao H, Kubo H, Berretta RM, Chen X, et al. β1-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways. American Journal of Physiology - Heart and Circulatory Physiology. 2010;299:H322–H31. [PubMed]
59. MacDonnell SM, Weisser-Thomas J, Kubo H, Hanscome M, Liu Q, Jaleel N, et al. CaMKII Negatively Regulates Calcineurin-NFAT Signaling in Cardiac Myocytes. Circ Res. 2009;105:316–25. [PMC free article] [PubMed]
60. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004;94:110–8. [PubMed]
61. Mann DL. Mechanisms and Models in Heart Failure: A Combinatorial Approach. Circulation. 1999;100:999–1008. [PubMed]
62. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. The Journal of Clinical Investigation. 2003;111:859–67. [PMC free article] [PubMed]
63. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198–205. [PubMed]
64. Seth M, Zhang Z-S, Mao L, Graham V, Burch J, Stiber J, et al. TRPC1 Channels Are Critical for Hypertrophic Signaling in the Heart. Circ Res. 2009;105:1023–30. [PMC free article] [PubMed]